NCT07434388Completed
LRFN5 and OLFM4 in Schizophrenia
Low Levels of LRFN5 and OLFM4 in Schizophrenia May Be Associated With Synaptic Regulation and Immunoinflammatory Abnormalities
Source: ClinicalTrials.gov · Last updated 25 Feb 2026
Brief summary (registry, in English)
This cross-sectional observational study evaluated serum levels of Leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and Olfactomedin-4 (OLFM4) in patients with schizophrenia during acute exacerbation and in healthy controls. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in schizophrenia.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 60 (actual)
- First submitted
- 20 Feb 2026
- Start date
- 27 Apr 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Elazığ Mental Health and Diseases Hospital
- Diseases
- Schizophrenia
- NCT number
- NCT07434388
What you commit to
- Study type: Observational
- Participants enrolled: 60
- From 27 Apr 2025 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- For Schizophrenia Group:
- \*Inclusion Criteria:
- Diagnosis of schizophrenia according to DSM-5-TR
- Acute exacerbation requiring hospitalization
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Schizophrenia Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than schizophrenia
- Alcohol/drug/substance use
- For Healthy Control Group:
- \*Inclusion Criteria:
- No psychiatric diagnosis
- No systemic or immunological illness
- Medication-free for at least one month
- Age ≥ 18 years and \< 65 years
- Provided informed consent
- For Healthy Control Group:
- \*Exclusion Criteria:
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than schizophrenia
- Alcohol/drug/substance use
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Elazığ Mental Health and Diseases Hospital Psychiatry Clinic Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.